Karachi: Eli Lilly Pakistan Pvt. Ltd, the manufacturer of Humalog medical insulin that is used to treat Diabetes Mellitus has decided to shut its manufacturing offices in the country. However, the decision seems to be ill-timed for the booming pharmaceutical industry.
Being a multinational company, Eli Lilly maintains the sole responsibility of maintaining quality and effectiveness of their product. However, under the clashing ideologies between local government and the International Manufacturers, Eli Lilly was left with no other choice but to withdraw its operations.
According to the manufacturers, the government is not concerned with the quality, safety, and efficiency of insulin. For political reasons, the focus remains on the price of the product.
The US-based manufacturers stated that due to the inability to provide decent quality, efficient insulin at shockingly low costs, the company shall be left with no choice but to shut down operations.
However, representatives of the company stated that their product shall still be available to purchase in the market, regardless of their inactive manufacturing services. A letter released by the company said
“We remain committed to helping patients who need our medicines; and therefore, Lilly will continue to make our products available in Pakistan through our distributor, AGCL,”
This will not only adversely affect the rising population of diabetic individuals in Pakistan, but also lessen options for good quality injectable insulin in Pakistan.